Pfizer Inc. (NYSE:PFE) Holdings Lowered by McKinley Carter Wealth Services Inc.

McKinley Carter Wealth Services Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 16.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,892 shares of the biopharmaceutical company’s stock after selling 2,015 shares during the quarter. McKinley Carter Wealth Services Inc.’s holdings in Pfizer were worth $262,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Foster Victor Wealth Advisors LLC boosted its stake in shares of Pfizer by 24.9% during the 4th quarter. Foster Victor Wealth Advisors LLC now owns 564,035 shares of the biopharmaceutical company’s stock worth $14,834,000 after acquiring an additional 112,616 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its stake in Pfizer by 41.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 6,377,817 shares of the biopharmaceutical company’s stock valued at $169,203,000 after acquiring an additional 1,879,504 shares in the last quarter. Asset Dedication LLC grew its position in Pfizer by 107.4% during the fourth quarter. Asset Dedication LLC now owns 26,833 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 13,896 shares in the last quarter. BSW Wealth Partners boosted its stake in shares of Pfizer by 2.1% during the 4th quarter. BSW Wealth Partners now owns 52,935 shares of the biopharmaceutical company’s stock valued at $1,404,000 after buying an additional 1,111 shares during the period. Finally, Patriot Financial Group Insurance Agency LLC grew its stake in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock valued at $1,027,000 after purchasing an additional 391 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on PFE. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, Guggenheim decreased their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.65 on Thursday. The firm has a 50 day simple moving average of $26.18 and a 200 day simple moving average of $27.91. The firm has a market cap of $151.00 billion, a P/E ratio of 36.01, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.46%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.